Alemtuzumab is a recombinant humanized monoclonal antibody directed against the cell surface antigen CD52. Structurally, it belongs to the immunoglobulin G1 kappa (IgG1κ) subclass and is composed of two identical heavy chains and two identical light chains, forming a Y-shaped molecule with a molecular weight of approximately 150 kilodaltons (kDa). The antibody was developed by grafting complementarity-determining regions (CDRs) from a murine antibody (Campath-1) into a human IgG1 framework, which preserves antigen-binding specificity while reducing nonhuman immunogenic elements.
Each Fab region of Alemtuzumab is responsible for antigen recognition and binds with high affinity to CD52, a small glycoprotein anchored in the plasma membrane via a glycosylphosphatidylinositol (GPI) linkage. CD52 is widely expressed on the surface of mature lymphocytes, including B and T cells, as well as on monocytes and some granulocytes. The binding epitope for Alemtuzumab lies within the peptide and carbohydrate portions of the CD52 molecule, and the antibody interacts through its variable domains, primarily via hydrogen bonding and shape complementarity.
The Fc region of Alemtuzumab mediates immune effector functions after antigen binding through interactions with complement component C1q and Fc gamma receptors (FcγRs) on immune cells. These interactions can trigger immune mechanisms such as complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC), leading to targeted cell depletion in experimental models. Biophysically, Alemtuzumab displays a long half-life in circulation due to neonatal Fc receptor (FcRn) recycling, contributing to sustained presence at target sites.
InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.
How similar are these biosimilars to the original therapeutic antibody?
Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.
Are these antibodies suitable for in vivo studies?
Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.
What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?
A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.
What quality and purity standards do biosimilar antibodies meet?
All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.
Which therapeutic targets and mechanisms are covered in the Biosimilar line?
The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.
Have a product or application question? Consult our FAQs or contact us.
